ILT5 reactivity among different patient groups and healthy donors
| Patient or donor group . | No. of sera tested . | ILT5- reactive, no. (%) . | ILTv1, no. (%) . | ILTv2, no. (%) . |
|---|---|---|---|---|
| Allogeneic HSCT patients (n = 240) | 737 | 13 (5.4) | 11 (4.6) | 2 (0.8) |
| Renal transplantation recipients (n = 105) | 105 | 0 (0) | 0 | 0 |
| Patients with collagen diseases* (n = 40) | 40 | 0 (0) | 0 | 0 |
| Multiparous females (n = 80) | 80 | 0 (0) | 0 | 0 |
| Polytransfused patients (n = 13) | 13 | 0 (0) | 0 | 0 |
| Healthy donors (n = 30) | 30 | 0 (0) | 0 | 0 |
| Patient or donor group . | No. of sera tested . | ILT5- reactive, no. (%) . | ILTv1, no. (%) . | ILTv2, no. (%) . |
|---|---|---|---|---|
| Allogeneic HSCT patients (n = 240) | 737 | 13 (5.4) | 11 (4.6) | 2 (0.8) |
| Renal transplantation recipients (n = 105) | 105 | 0 (0) | 0 | 0 |
| Patients with collagen diseases* (n = 40) | 40 | 0 (0) | 0 | 0 |
| Multiparous females (n = 80) | 80 | 0 (0) | 0 | 0 |
| Polytransfused patients (n = 13) | 13 | 0 (0) | 0 | 0 |
| Healthy donors (n = 30) | 30 | 0 (0) | 0 | 0 |
Including patients with rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis.